VSTM insider trading
NasdaqCM HealthcareVerastem, Inc.: insider trade history from SEC Form 4 filings.
About Verastem, Inc.
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Company website: www.verastem.com
VSTM insider activity at a glance
FilingIQ tracks 267 insider transactions for VSTM in filings since Jan 7, 2015. The most recent transaction is dated Oct 1, 2026.
Across the full history, 29 open-market purchases
and 163 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on VSTM insider trades is 56.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest VSTM Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for VSTM?
- FilingIQ tracks 267 Form 4 insider transactions for VSTM (Verastem, Inc.), covering filings from Jan 7, 2015 onwards. 6 of those are dated within the last 90 days.
- Are VSTM insiders net buyers or net sellers?
- Across the full Form 4 history for VSTM, 29 transactions (11%) were open-market purchases and 163 (61%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does VSTM insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is VSTM in?
- Verastem, Inc. (VSTM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $444.01M.
Methodology & sources
Every VSTM insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.